---
title: "Reproductive Safety of Vortioxetine in Pregnancy: Prospective Registry Data"
id: "womens-mental-health-0-new-research-from-the-cwmh-data-on-the-reproductive-safety-of-vortioxetine"
canonical_url: "https://medichelpline.com/clinical-feed/womens-mental-health-0-new-research-from-the-cwmh-data-on-the-reproductive-safety-of-vortioxetine"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "Women's Mental Health"
source_url: "https://womensmentalhealth.org/posts/vortioxetine-pregnancy-reproductive-safety/"
published_at: "2026-08-12T12:00:29.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Reproductive Safety of Vortioxetine in Pregnancy: Prospective Registry Data
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/womens-mental-health-0-new-research-from-the-cwmh-data-on-the-reproductive-safety-of-vortioxetine
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** Women's Mental Health
- **Source URL:** [Original Journal Publication](https://womensmentalhealth.org/posts/vortioxetine-pregnancy-reproductive-safety/)
- **Published At:** 2026-08-12T12:00:29.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- New prospective data from the MGH National Pregnancy Registry report outcomes for **56** pregnancies with first‑trimester exposure to **vortioxetine** (Trintellix). - No **major malformations** were observed among the 56 evaluable exposures. - Data collection used prospective enrollment, maternal postpartum interviews, medical record review, and adjudication by a dysmorphologist blinded to exposure. - The cohort size remains small; absence of observed malformations does not exclude a modest increase in risk or rare defects. - The analysis focused on major structural malformations after first‑trimester exposure and did not assess miscarriage, pregnancy complications, preterm birth, neonatal adaptation, or long‑term neurodevelopment. - Because vortioxetine is a newer antidepressant (approved in the US in 2013), prior pregnancy exposure data have been limited; these findings add systematically collected information but are preliminary. - Clinical decisions should be individualized: consider the mother’s illness severity, prior medication response, risks of untreated depression, and the comparative reproductive safety data for alternative antidepressants. - Continued enrollment in the National Pregnancy Registry for Psychiatric Medications is important to obtain larger, more precise estimates; the registry enrolls pregnant people age 45 and younger and accepts those who did and did not take antidepressants during pregnancy. - Contact information for the registry was provided in the source (phone 1-866-961-2388) and the primary study is cited (Journal of Clinical Psychopharmacology).
## Clinical Analysis & Structured Key Points
[Skip to content](https://womensmentalhealth.org/posts/vortioxetine-pregnancy-reproductive-safety/#content) [![mgh_logo](https://womensmentalhealth.org/wp-content/uploads/2025/02/myIcon.svg)](https://www.massgeneral.org/) [![Harvard-Medical-School-logo](https://womensmentalhealth.org/wp-content/uploads/2025/01/Harvard-Medical-School-logo.png)](https://hms.harvard.edu/) [ ![MGH Center for Women's Mental Health Logo](https://womensmentalhealth.org/wp-content/uploads/2025/04/MGH-logo-400x98-1.jpg) ](https://womensmentalhealth.org/) * [About](https://womensmentalhealth.org/about/) * [Mission Statement](https://womensmentalhealth.org/about/mission-statement/) * [Staff](https://womensmentalhealth.org/about/staff/) * [Our Publications](https://womensmentalhealth.org/about/our-publications/) * [Location](https://womensmentalhealth.org/about/directions/) * [Support Our Program](https://giving.massgeneral.org/donate/ammon-pinizzotto-center/) * [Join Our Team](https://womensmentalhealth.org/join-our-team-2/) * [Contact Us](https://womensmentalhealth.org/about/contact-us/) * [Specialty Areas](https://womensmentalhealth.org/specialty-clinics/) * [PMS & PMDD](https://womensmentalhealth.org/specialty-clinics/pms-and-pmdd/) * [Fertility & Mental Health](https://womensmentalhealth.org/specialty-clinics/infertility-and-mental-health/) * [Perinatal Substance Use](https://womensmentalhealth.org/specialty-clinics/perinatal-substance-use/) * [Psychiatric Disorders During Pregnancy](https://womensmentalhealth.org/specialty-clinics/psychiatric-disorders-during-pregnancy/) * [Pregnancy & Medications](https://womensmentalhealth.org/specialty-clinics/pregnancy-medications/) * [Postpartum Psychiatric Disorders](https://womensmentalhealth.org/specialty-clinics/postpartum-psychiatric-disorders-2/) * [Breastfeeding & Medications](https://womensmentalhealth.org/specialty-clinics/breastfeeding-and-psychiatric-medication-2/) * [Menopausal Symptoms](https://womensmentalhealth.org/specialty-clinics/menopausal-symptoms/) * [Blog](https://womensmentalhealth.org/blog/recent-posts/) * [Read the Latest Blog](https://womensmentalhealth.org/blog/recent-posts/) * [Podcast](https://sogladyouasked.org/) * [Resource Hub – Sleep Challenge](https://womensmentalhealth.org/resource-hub-sleep-challenges/) * [Resource Hub – Bipolar Disorder and Pregnancy](https://womensmentalhealth.org/resource-hub-bipolar-disorder-pregnancy/) * [Resource Hub for Postpartum Anxiety](https://womensmentalhealth.org/resource-hub-postpartum-anxiety/) * [Documentary](https://www.morethanbluedocumentary.com/) * [Clinical Program](https://womensmentalhealth.org/clinical-program/) * [Research](https://womensmentalhealth.org/research/) * [Education](https://womensmentalhealth.org/educational-program/) * [The Nurse Practitioner Masterclass](https://womensmentalhealth.org/thenpmasterclass/) * [The Psychiatry Collective](https://womensmentalhealth.org/thepsychiatrycollective/) * [Collective Members](https://womensmentalhealth.org/psychiatrycollectiveproviderlistings/) * [Resources](https://womensmentalhealth.org/resource/) * [Contact](https://womensmentalhealth.org/about/contact-us/) * [Contact Us](https://womensmentalhealth.org/about/contact-us/) * [Support Our Program](https://giving.massgeneral.org/donate/ammon-pinizzotto-center/) * [](https://womensmentalhealth.org/posts/vortioxetine-pregnancy-reproductive-safety/ "Search") Search [](https://womensmentalhealth.org/posts/vortioxetine-pregnancy-reproductive-safety/) * [About](https://womensmentalhealth.org/about/) * [Mission Statement](https://womensmentalhealth.org/about/mission-statement/) * [Staff](https://womensmentalhealth.org/about/staff/) * [Our Publications](https://womensmentalhealth.org/about/our-publications/) * [Location](https://womensmentalhealth.org/about/directions/) * [Support Our Program](https://giving.massgeneral.org/donate/ammon-pinizzotto-center/) * [Join Our Team](https://womensmentalhealth.org/join-our-team-2/) * [Contact Us](https://womensmentalhealth.org/about/contact-us/) * [Specialty Areas](https://womensmentalhealth.org/specialty-clinics/) * [PMS & PMDD](https://womensmentalhealth.org/specialty-clinics/pms-and-pmdd/) * [Fertility & Mental Health](https://womensmentalhealth.org/specialty-clinics/infertility-and-mental-health/) * [Perinatal Substance Use](https://womensmentalhealth.org/specialty-clinics/perinatal-substance-use/) * [Psychiatric Disorders During Pregnancy](https://womensmentalhealth.org/specialty-clinics/psychiatric-disorders-during-pregnancy/) * [Pregnancy & Medications](https://womensmentalhealth.org/specialty-clinics/pregnancy-medications/) * [Postpartum Psychiatric Disorders](https://womensmentalhealth.org/specialty-clinics/postpartum-psychiatric-disorders-2/) * [Breastfeeding & Medications](https://womensmentalhealth.org/specialty-clinics/breastfeeding-and-psychiatric-medication-2/) * [Menopausal Symptoms](https://womensmentalhealth.org/specialty-clinics/menopausal-symptoms/) * [Blog](https://womensmentalhealth.org/blog/recent-posts/) * [Read the Latest Blog](https://womensmentalhealth.org/blog/recent-posts/) * [Podcast](https://sogladyouasked.org/) * [Resource Hub – Sleep Challenge](https://womensmentalhealth.org/resource-hub-sleep-challenges/) * [Resource Hub – Bipolar Disorder and Pregnancy](https://womensmentalhealth.org/resource-hub-bipolar-disorder-pregnancy/) * [Resource Hub for Postpartum Anxiety](https://womensmentalhealth.org/resource-hub-postpartum-anxiety/) * [Documentary](https://www.morethanbluedocumentary.com/) * [Clinical Program](https://womensmentalhealth.org/clinical-program/) * [Research](https://womensmentalhealth.org/research/) * [Education](https://womensmentalhealth.org/educational-program/) * [The Nurse Practitioner Masterclass](https://womensmentalhealth.org/thenpmasterclass/) * [The Psychiatry Collective](https://womensmentalhealth.org/thepsychiatrycollective/) * [Collective Members](https://womensmentalhealth.org/psychiatrycollectiveproviderlistings/) * [Resources](https://womensmentalhealth.org/resource/) * [Contact](https://womensmentalhealth.org/about/contact-us/) * [Contact Us](https://womensmentalhealth.org/about/contact-us/) * [Support Our Program](https://giving.massgeneral.org/donate/ammon-pinizzotto-center/) Search Results for **{phrase}** (**{results_count}** of **{results_count_total}**) Displaying **{results_count}** results of **{results_count_total}** Generic filters Exact matches only Search in title Search in content Search in excerpt # New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine * August 12, 2026 # New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine * [Medications and Pregnancy](https://womensmentalhealth.org/posts/category/medications-and-pregnancy/) | [Research at CWMH](https://womensmentalhealth.org/posts/category/research-at-cwmh/) | [Risk of Malformations](https://womensmentalhealth.org/posts/category/risk-of-malformations/) New prospective data on 56 first-trimester vortioxetine exposures found no major malformations, offering reassuring but still preliminary reproductive safety information. ![Picture of MGH Center for Women's Mental Health](https://secure.gravatar.com/avatar/40b1b2618fc4f7a026722b2e4da1d897c5069bf9ff9add1d813ff62911707848?s=100&d=mm&r=g) #### MGH Center for Women's Mental Health ![](https://womensmentalhealth.org/wp-content/uploads/elementor/thumbs/73821292_pregnant-woman-taking-medicine-at-home-scaled-e1785161044112-rr0zf8bkl97hlj6b8ysy5bwjdursj9y9tlc3mrnh1g.jpg) In This article * This prospective case series included 56 women who used vortioxetine during the first trimester of pregnancy. * No major malformations were observed among the 56 exposed pregnancies with evaluable data. * Prospective enrollment, medical-record review, and blinded outcome assessment strengthen the findings. * The results are reassuring, but the small sample and absence of a comparison group limit the conclusions that can be drawn. * Continued enrollment in the National Pregnancy Registry is essential for obtaining more precise reproductive safety data on vortioxetine and other newer antidepressants. Vortioxetine (Trintellix) is an antidepressant used for the treatment of major depressive disorder in adults. While we have a considerable amount of information supporting the reproductive safety of older antidepressants, including most selective serotonin reuptake inhibitors (SSRIs), the serotonin-norepinephrine reuptake inhibitors (SNRIs) venlafaxine and duloxetine, and bupropion, we have far less information on newer antidepressants. Vortioxetine was approved in the United States in 2013 for the treatment of depression. Because it is a relatively newer antidepressant, the number of reported pregnancies with vortioxetine exposure has been small. Analyzing data from the MGH National Pregnancy Registry for Psychiatric Medications, [Freeman and colleagues now report additional prospective data](https://pubmed.ncbi.nlm.nih.gov/42370714/) on the risk of major malformations following first-trimester exposure to vortioxetine. ## **The National Pregnancy Registry** The [National Pregnancy Registry for Psychiatric Medications](https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/) is a prospective pharmacovigilance program. Pregnant women with a history of psychiatric illness are enrolled during pregnancy and followed through the postpartum period. Information is collected before the pregnancy outcome is known, an important feature that reduces the risk of recall and reporting bias. For this analysis, the investigators: * Identified women enrolled in the Registry who reported taking vortioxetine during the first trimester * Collected information about major malformations through a maternal postpartum interview and review of medical records * Used a dysmorphologist who was blinded to medication exposure to make the final determination regarding major malformations As of March 26, 2026, 56 women with first-trimester exposure to vortioxetine had evaluable outcome data. ## **No Major Malformations Observed After First-Trimester Exposure** Among the 56 women who used vortioxetine during the first trimester, no major malformations were observed. * **Vortioxetine-exposed pregnancies:** 0 of 56 with a major malformation * **Outcome assessment:** Maternal postpartum interview, medical-record review, and adjudication by a dysmorphologist blinded to exposure status These preliminary findings are reassuring. The new study did not identify a signal suggesting that vortioxetine is a major teratogen. **Reassuring Findings, But More Research is Needed** The new Registry findings add important information to a previously sparse literature. The study provides systematically collected data because women were enrolled prospectively and outcomes were assessed through postpartum interviews and medical-record review. At the same time, the sample remains small. Observing no malformations among 56 exposed pregnancies does not establish that vortioxetine is safe during pregnancy. These data cannot rule out a modest increase in risk, nor can they detect rare malformations. Much larger numbers of exposed pregnancies and an appropriate comparison group will be needed to generate a more precise estimate of risk. It is also important to note that the analysis focused on major malformations after first-trimester exposure. It does not provide information on other outcomes that may be relevant when an antidepressant is used during pregnancy, including miscarriage, pregnancy complications, preterm birth, neonatal adaptation symptoms, or longer-term neurodevelopmental outcomes. Taken together, these findings offer some reassurance regarding the risk of major malformations following first-trimester exposure to vortioxetine. However, treatment decisions must be individualized. When initiating an antidepressant in a person who is pregnant or planning pregnancy, it is reasonable to consider a medication with a better-characterized reproductive safety profile. For a patient who has responded well to vortioxetine, however, the potential benefits of switching medications must be weighed against the risk of relapse or loss of treatment response. No two situations are identical. Decisions regarding treatment should take into account the severity and recurrence of the mother’s illness, her response to previous medications, the availability of effective alternatives, and the risks associated with untreated depression during pregnancy. **The Registry Continues to Recruit** The[ National Pregnancy Registry for Antidepressants](https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/) continues to enroll pregnant people age 45 and younger with a history of psychiatric illness. People who have taken an antidepressant during pregnancy, as well as those who have not taken an antidepressant, are eligible to participate. Participation helps clinicians and patients make better-informed decisions about the use of antidepressant medications during pregnancy. To learn more, visit our website or call **1-866-961-2388**. —Ruta Nonacs, MD PhD Share: ### References Freeman MP, Viguera AC, Manuelian AM, Grassi EJ, Murphy BB, Cohen LS. [Pregnancy Outcomes After First-Trimester Exposure to Vortioxetine: Prospective Outcomes From the MGH National Pregnancy Registry for Psychiatric Medications.](https://pubmed.ncbi.nlm.nih.gov/42370714/) _Journal of Clinical Psychopharmacology_. Published online June 29, 2026. ## MOST RECENT * August 5, 2026 ## [So Glad You Asked Podcast: Lee Cohen, MD and Kristin Lasseter, MD on Postpartum Depression](https://womensmentalhealth.org/posts/so-glad-you-asked-podcast-post-partum-depression/) [ ![](https://womensmentalhealth.org/wp-content/uploads/2026/08/Ep.-8-Cover-Art-for-Blog-300x169.png) ](https://womensmentalhealth.org/posts/so-glad-you-asked-podcast-post-partum-depression/) * August 5, 2026 ## [Understanding Postpartum Psychosis: Beyond the Headlines](https://womensmentalhealth.org/posts/understanding-postpartum-psychosis/) [ ![](https://womensmentalhealth.org/wp-content/uploads/2021/07/sadwchild-300x207.jpg) ](https://womensmentalhealth.org/posts/understanding-postpartum-psychosis/) * July 29, 2026 ## [A New Home for More Than Blue](https://womensmentalhealth.org/posts/new-more-than-blue-website/) [ ![](https://womensmentalhealth.org/wp-content/uploads/2026/07/MTB-Web-Live-Announcement-1280-x-720-px-1-300x169.png) ](https://womensmentalhealth.org/posts/new-more-than-blue-website/) * July 28, 2026 ## [A New Website for So Glad You Asked](https://womensmentalhealth.org/posts/new-website-so-glad-you-asked/) [ ![](https://womensmentalhealth.org/wp-content/uploads/2026/01/Landscape-SGYA-Podcast-scaled-e1775740021400-300x169.png) ](https://womensmentalhealth.org/posts/new-website-so-glad-you-asked/) ## Keep Reading [ ![](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20450%20300'%3E%3C/svg%3E)](https://womensmentalhealth.org/posts/topiramate-topamax-associated-with-an-increased-risk-of-oral-clefts/) * February 8, 2012 ## [Topiramate (Topamax) Associated with an Increased Risk of Oral Clefts](https://womensmentalhealth.org/posts/topiramate-topamax-associated-with-an-increased-risk-of-oral-clefts/) [ ![](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20700%20441'%3E%3C/svg%3E)](https://womensmentalhealth.org/posts/good-news-data-use-adhd-medications-pregnancy/) * December 22, 2017 ## [Good News: More Data on the Use of ADHD Medications During Pregnancy](https://womensmentalhealth.org/posts/good-news-data-use-adhd-medications-pregnancy/) [ ![](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20450%20338'%3E%3C/svg%3E)](https://womensmentalhealth.org/posts/fda-proposes-major-revision-of-prescription-drug-labeling/) * June 10, 2008 ## [FDA Proposes Major Revision of Prescription Drug Labeling](https://womensmentalhealth.org/posts/fda-proposes-major-revision-of-prescription-drug-labeling/) [ ![](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20450%20338'%3E%3C/svg%3E)](https://womensmentalhealth.org/posts/methylphenidate-pregnancy-no-increase-risk-malformations/) * June 6, 2016 ## [Methylphenidate and Pregnancy: No Increase in Risk of Malformations](https://womensmentalhealth.org/posts/methylphenidate-pregnancy-no-increase-risk-malformations/) [![MGH logo white](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201000%20185'%3E%3C/svg%3E)](https://womensmentalhealth.org/) [](https://www.facebook.com/MGHwomensmentalhealth/ "Facebook") [](https://x.com/mghcwmh "Twitter") [](https://www.instagram.com/mghcwmh/ "Instagram") [](https://www.linkedin.com/company/womens-mental-health-mgh/ "LinkedIn") Perinatal and Reproductive Psychiatry Program Simches Research Building 185 Cambridge St Suite 2200 Boston, MA 02114 admin@womensmentalhealth.org [Support Our Program](https://giving.massgeneral.org/donate/ammon-pinizzotto-center/) #### Sign up for our newsletter Get the latest news in women’s mental health and our research. "*" indicates required fields Name This field is for validation purposes and should be left unchanged. Email* Δ Copyright 2026 MGH Center for Women's Mental Health | All Rights Reserved [Page load link](https://womensmentalhealth.org/posts/vortioxetine-pregnancy-reproductive-safety/) [ Go to Top ](https://womensmentalhealth.org/posts/vortioxetine-pregnancy-reproductive-safety/) Notifications [](javascript:; "Close")[](javascript:; "Next")[](javascript:; "Previous")
## Related Clinical Research

- [Short-Term Relaxation + Music Does Not Prevent Depression, Anxiety, or GI Symptoms in Military Rec](https://medichelpline.com/clinical-feed/pubmed-42763415.md) (DOI: 10.12659/MSM.953585)
- [Transcutaneous Auricular Vagus Nerve Stimulation for Acute Herpes Zoster Pain in Middle-Aged and E](https://medichelpline.com/clinical-feed/pubmed-42736127.md) (DOI: 10.3760/cma.j.cn112137-20260302-00587)
- [Atomoxetine and Stimulant Use in Pregnancy: Maternal and Birth Outcome Findings](https://medichelpline.com/clinical-feed/womens-mental-health-0-atomoxetine-and-stimulants-during-pregnancy-what-do-we-know-about-pregnancy.md)
- [Adverse reactions to azelastine and levocabastine: descriptive analysis from WHO VigiAccess](https://medichelpline.com/clinical-feed/plos-one-7-characterization-of-adverse-reactions-to-two-antihistamine-drugs-a-descriptive.md)
- [Understanding Parasitic Identification in Delusional Parasitosis](https://medichelpline.com/clinical-feed/plos-one-21-bridging-perception-and-reality-parasitic-identification-in-delusional.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.